Wall Street analysts call the CMS TAVR proposal a "clear positive" for the sector, with Edwards Lifesciences, Medtronic, and ...
The proposed Medicare coverage change could help Edwards Lifesciences gain market share from Medtronic and Boston Scientific, ...
On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) ...
Citi analyst Joanne Wuensch keeps a Buy rating on Edwards Lifesciences (EW) with an $81 price target after the company presented its EARLY TAVR clinical data, saying it came in better than expected ...
Edwards Lifesciences had a monumental Q4 and full year 2025, growing sales 13.3% to $1.57 billion in the last quarter of the year. The company’s TAVR and TMTT performance are largely being credited ...
MedPage Today on MSN
Midterm TAVR data turn muddy: Will 10 years even suffice for a verdict?
Real-world mortality complicates reassurances in trial results ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
Edwards Lifesciences (EW) announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results